First Regimen I patient enters Active Treatment Extension
Filed with ASX · · 3 pages · English
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- R&D Facility Extension and Second Drawdown Completed
- Change in substantial holding
- Section 708A Cleansing Statement
- Application for quotation of securities - NUZ
- Investor webinar reminder and presentation
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics